Combination therapy with a compound acting as a platelet ADP receptor inhibitor
| Title: | Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
|---|---|
| Patent Number: | 8,946,219 |
| Publication Date: | February 03, 2015 |
| Appl. No: | 12/908837 |
| Application Filed: | October 20, 2010 |
| Abstract: | The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases. |
| Inventors: | Conley, Pamela B. (Palo Alto, CA, US); Andre, Patrick (San Mateo, CA, US); Sinha, Uma (San Francisco, CA, US) |
| Assignees: | Portola Pharmaceuticals, Inc. (South San Francisco, CA, US) |
| Claim: | 1. A method for treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of the following therapeutic agents: [chemical expression included] or a pharmaceutically acceptable salt thereof; and (2) betrixaban or a pharmaceutically acceptable salt thereof. |
| Claim: | 2. The method according to claim 1 , wherein the pharmaceutically acceptable salt of betrixaban is the maleate salt. |
| Claim: | 3. The method according to claim 1 , wherein at least one of the therapeutic agents is administered in a sub-therapeutic dosage. |
| Claim: | 4. The method according to claim 1 , wherein both of the therapeutic agents are administered in sub-therapeutic dosages. |
| Claim: | 5. The method according to claim 1 , wherein the two therapeutic agents are administered simultaneously. |
| Claim: | 6. The method according to claim 1 , wherein the two therapeutic agents are administered sequentially. |
| Claim: | 7. The method of claim 1 , comprising administering to said mammal a therapeutically effective amount of the following three therapeutic agents: [chemical expression included] or a pharmaceutically acceptable salt thereof; (2) an antiplatelet agent; and (3) betrixaban or a pharmaceutically acceptable salt thereof. |
| Claim: | 8. The method according to claim 7 , wherein the pharmaceutically acceptable salt of betrixaban is the maleate salt. |
| Claim: | 9. The method according to claim 7 , wherein at least one of the therapeutic agents is administered in a sub-therapeutic dosage. |
| Claim: | 10. The method according to claim 7 , wherein all of the therapeutic agents are administered in sub-therapeutic dosages. |
| Claim: | 11. The method according to claim 7 , wherein the three therapeutic agents are administered simultaneously. |
| Claim: | 12. The method according to claim 7 , wherein the three therapeutic agents are administered sequentially. |
| Claim: | 13. The method according to claim 1 , wherein the pharmaceutically acceptable salt of [chemical expression included] is the potassium salt or sodium salt. |
| Current U.S. Class: | 514/247 |
| Patent References Cited: | 6376515 April 2002 Zhu et al. 6509348 January 2003 Olgetree 6835739 December 2004 Zhu et al. 6844367 January 2005 Bing-Yan et al. 7022695 April 2006 Bing-Yan et al. 7285565 October 2007 Bing-Yan et al. 7312325 December 2007 Bing-Yan et al. 7314874 January 2008 Bing-Yan et al. 7342013 March 2008 Bing-Yan et al. 7727981 June 2010 Bing-Yan et al. 7767697 August 2010 Song et al. 2002/0077486 June 2002 Scarborough et al. 2003/0109543 June 2003 Ogletree 2006/0100193 May 2006 Zhu et al. 2007/0112039 May 2007 Grant et al. 2007/0123547 May 2007 Scarborough et al. 2007/0185092 August 2007 Zhu et al. 2007/0259924 November 2007 Zhu et al. 2008/0153876 June 2008 Sinha et al. 2008/0254036 October 2008 Sinha et al. 2008/0293701 November 2008 Zhao et al. 2009/0186810 July 2009 Zwaal et al. WO 00/47207 August 2000 WO 01/19788 March 2001 WO 01/40231 June 2001 WO 03/011872 February 2003 WO 2005/035520 April 2005 WO 2006/045756 May 2006 WO 2007/056219 May 2007 |
| Other References: | Yamazaki, et al., Thrombosis and circulation, vol. 15, No. 1, 102-105, (2007). cited by applicant US 7,479,487, 1/2009, Bing-Yan et al. (withdrawn). cited by applicant International Search Report, dated Dec. 12, 2008. cited by applicant |
| Primary Examiner: | Chong, Yong |
| Attorney, Agent or Firm: | Sheppard Mullin Richter & Hampton LLP |
| Accession Number: | edspgr.08946219 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|